FINWIRES · TerminalLIVE
FINWIRES

$ADUS

10 stories mentioning ADUSUpdated 6d ago

Every FINWIRES story that references ADUS, newest first.

What are analysts saying about ADUS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ADUS?

Wire

Addus HomeCare's Acquisition of AccentCare's Personal Care Business Likely to Support Growth, UBS Says

Addus HomeCare' (ADUS) $275 million acquisition of AccentCare's personal care division will likely support its growth objectives in 2027 and 2028, UBS Securities said in a note Tuesday.The deal, expected to close in H1 2027, will likely be immediately accretive and will also boost the company's "already strong presence in Illinois and Texas," the note said.While the acquisition will increase Addus' exposure to the Medicaid program in the two states, it will also provide a "considerable opportunity to leverage its existing infrastructure in those two states creating ample synergy opportunities over time," the bank said.UBS said that Addus indicated that without any synergies or a $33 million tax benefit, the purchase multiple is 10.8 times current EBITDA. When including the near-term tax benefit, the deal valuation goes down to 9.5 times current EBITDA, the note said."First year synergies seem likely to further bring the multiple paid down by one turn, with further upside (revenue and margin gains) expected in year two and beyond," the note said.UBS also said it believes the fundamental outlook for Addus "remains positive as the company benefits from secular trends such as baby boomers beginning to age into their 80s."UBS has a buy rating on Addus and a $145 price target.Price: $116.14, Change: $-1.19, Percent Change: -1.02%

$ADUS
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, Capricor Therapeutics' (CAPR) shares gained 5.1% after B. Riley upgraded the biotechnology company's stock to buy from neutral, and raised its price target to $21 from $5.Summit Therapeutics (SMMT) shares rose 5.2% in Monday trading, a day after the company said its partner Akeso reported updated data, including overall survival, from the phase 3 HARMONi-2 trial of investigational bispecific antibody ivonescimab, showing a 27% reduction in the risk of death compared with pembrolizumab.Addus HomeCare (ADUS) agreed to acquire AccentCare's personal care operations outside of New York in a deal worth roughly $275 million, adding to a series of recent acquisitions. Addus HomeCare shares were up 0.3%.Abbott Laboratories (ABT) agreed to pay about $385 million to resolve allegations that infant formula produced at the company's Sturgis, Michigan, facility failed to meet statutory, regulatory, and contractual requirements, the US Department of Justice said. Abbott shares were up 1.1%.

$ABT$ADUS$CAPR$SMMT
Sectors

Sector Update: Healthcare

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, Addus HomeCare (ADUS) agreed to acquire AccentCare's personal care operations outside of New York in a deal worth roughly $275 million, adding to a series of recent acquisitions. Addus HomeCare shares were down 0.2%.

$ADUS
Addus Advances M&A Strategy With Deal for AccentCare Personal Care Business
US Markets

Addus Advances M&A Strategy With Deal for AccentCare Personal Care Business

Addus HomeCare (ADUS) agreed to acquire AccentCare's personal care operations outside of New York in a deal worth roughly $275 million, adding to a series of recent acquisitions.The AccentCare transaction substantially strengthens Addus' personal care service capabilities in Texas, Illinois, California and Arizona, while adding operations in Colorado, Georgia, Minnesota, Pennsylvania, Tennessee and Washington, it said Monday.The acquired AccentCare operations serve an average daily census of about 13,700 customers. The deal doesn't include the firm's hospice and home health operations.The transaction is in line with Addus' growth strategy and is projected to add about $280 million in annualized personal care revenue, representing an increase of around 19% to its revenue base, Chief Executive Dirk Allison said in a statement. The transaction should be accretive to the firm's results, according to Allison.Addus bought the personal care operations of Del Cielo Home Care Services in October and of HomeCourt Home Care in May 2026.Indiana-based HomeCourt has about $9.7 million in annualized revenue, Addus said in May, adding that it had agreed to acquire additional Indiana operations "of a similar size."Last month, the company reported second-quarter net service revenue of $377.4 million, up from $349.4 million a year earlier, with personal care contributing almost $296 million to the latest top-line.At the time, Allison said the company was looking to expand its market reach and increase its geographic footprint."With our strong cash flow in the second quarter, we reduced our bank debt to $64.3 million, leaving us with the financial flexibility to consider larger acquisition opportunities," Allison told analysts on an Aug. 4 earnings conference call, according to a FactSet transcript.Separately, BofA Securities said Monday it downgraded its rating on the Addus stock to neutral from buy and reduced its price objective to $125 from $140, citing slowing organic growth.Every 1% cut to Medicaid rates likely reflects a 6% hit to the company's earnings before interest, taxes, depreciation and amortization before any offsets, according to the brokerage. "Even if there are no cuts, the slowing rate growth means it's incrementally harder to grow given cost inflation," BofA analyst Joanna Gajuk said in a note to clients."The stock might get a lift near term ahead of elections, but next data points will be (2028) state budgets, which are likely to look worse than (2027) given the cuts to Medicaid under the (One Big Beautiful Bill Act) accumulate," Gajuk wrote. "Meanwhile, (Addus) could do larger deals as consolidation accelerates."Addus' stock was down 0.3% intraday Monday and has gained 8.7% so far this year.Price: $116.72, Change: $-0.38, Percent Change: -0.32%

$ADUS
Wire

Addus HomeCare Consolidation Can't Offset Medicaid Funding Pressures, BofA Says

Addus HomeCare's (ADUS) exposure to Medicaid funding pressures is expected to be offset by potential benefits from industry consolidation, although slowing state reimbursement rates could constrain growth, BofA Securities said in a Monday note.The brokerage expects state budget pressures to slow Medicaid rate increases for personal care services to about 1% on average in 2027, with Illinois, which accounts for 42% of Addus' personal care revenue, expected to have flat rates in 2027 and Texas, representing 20%, expected to remain flat through September 2027.BofA noted that with about 75% of Addus' revenue tied to Medicaid, the company is highly exposed to funding changes. A 1% Medicaid rate cut could lower EBITDA by about 6%, before offsets, while slower rate growth could limit the company's ability to offset cost inflation.Management could pursue larger acquisitions as industry consolidation accelerates, but M&A is unlikely to fully offset broader Medicaid funding pressures, with additional risks expected in 2028 as states face further funding cuts, the report added.BofA downgraded the stock to neutral from buy and lowered its price target to $125 from $140.Addus HomeCare shares were down 1.8% in Monday trading.Price: $115.11, Change: $-1.98, Percent Change: -1.69%

$ADUS
Research

Update: BofA Downgrades Addus HomeCare to Neural From Buy, Adjusts PT to $125 From $140

(Updated to include prior price target in headline.)Addus HomeCare (ADUS) has an average rating of overweight and mean price target of $133.69, according to analysts polled by FactSet.

$ADUS
Research

BofA Downgrades Addus HomeCare to Neural From Buy, Price Target is $125

Addus HomeCare (ADUS) has an average rating of overweight and mean price target of $133.69, according to analysts polled by FactSet.

$ADUS
Wire

Addus HomeCare COO Heather Dixon Departs; Brad Bickham Appointed as 1-Year Interim

Addus HomeCare (ADUS) said Chief Operating Officer and President Heather Dixon is no longer with the company.Former COO and President Brad Bickham has returned as COO on an interim basis for a one-year term, effective immediately, the company said Monday in a statement.Price: $120.07, Change: $+0.39, Percent Change: +0.33%

$ADUS
Wire

Addus HomeCare Q2 Momentum Seen Continuing, RBC Says

Addus HomeCare (ADUS) reported impressive Q2 organic growth across its core personal care and hospice segments, while home health volume shows encouraging signs of inflection, RBC Capital Markets said in a Wednesday note.While the hospice segment's $3 million Q2 cap accrual raised some client concerns, management reiterated its disciplined approach to patient and referral mix, which should prevent a further cap accrual this year, according to the note.Same-store census remains modestly negative year over year, but Illinois and New Mexico are now posting sequential and year-over-year census growth, while trends in Texas remain flattish. The company expects Texas to follow the same trajectory in the second half of 2026, driven by a caregiver app rollout, the note added.The proposed 2.1% net home health rate increase for 2027 is the first positive update in several years and is beginning to unlock M&A conversations in skilled home health, the brokerage said.RBC maintained its outperform rating on Addus HomeCare and raised its price target to $134 from $130.Shares of Addus HomeCare were up 2.1% in Wednesday trading.Price: $116.02, Change: $+2.36, Percent Change: +2.08%

$ADUS
Wire

Addus HomeCare's Personal Care Segment Drove Q2 Beat, UBS Says,

Addus HomeCare's (ADUS) Q2 results were led by strong performance in its personal care segment, which accounted for 78% of revenue and remained the company's key growth driver, UBS Securities said Monday in a report.Personal care revenue rose 10% to $296 million from a year earlier, $4.5 million ahead of consensus, supported by higher billable hours and improved rates in Illinois and Texas, the report said. Hospice trends were steady, while home health remained a small but strategic part of the portfolio, UBS said.Addus continues to evaluate clinical and nonclinical acquisition opportunities to expand market density and geographic reach, the report said.UBS maintained its buy rating on Addus stock and its $145 price target.Price: $113.51, Change: $-3.28, Percent Change: -2.81%

$ADUS

Track with the FINWIRES app suite